Bioavailability of once- and twice-daily regimens of didanosine in human immunodeficiency virus-infected children.
Antimicrob Agents Chemother 2000;
44:1375-6. [PMID:
10770783 PMCID:
PMC89876 DOI:
10.1128/aac.44.5.1375-1376.2000]
[Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The bioavailability of didanosine at 180 mg/m(2) once daily was compared to that at 90 mg/m(2) twice daily in 24 children with advanced human immunodeficiency virus infection. Children were studied at steady state using optimal sampling and prior pharmacokinetic parameter estimates. Relative bioavailability was 0. 95 +/- 0.49, supporting the potential clinical adequacy of once-daily dosing.
Collapse